Table 2 Summary of all adverse events reported by investigators in patients treated by nintedanib + pembrolizumab
Nintedanib dose | Grade 1–2 | Grade 3–4 | ||
|---|---|---|---|---|
150 mg BID | 200 mg BID | 150 mg BID | 200 mg BID | |
Alanine aminotransferase increased | 1 (16.7%) | 1 (16.7%) | 0 | 3 (50%) |
Aspartate aminotransferase increased | 1 (16.7%) | 0 | 0 | 2 (33%) |
Diarrhea | 3 (50%) | 1 (16.7%) | 0 | 0 |
Hypothyroidism | 2 (33%) | 1 (16.7%) | 0 | 0 |
Nausea | 2 (33%) | 1 (16.7%) | 0 | 0 |
Vomiting | 2 (33%) | 1 (16.7%) | 0 | 0 |
GGT increased | 0 | 1 (16.7%) | 0 | 1 (16.7%) |
Fatigue | 1 (16.7%) | 1 (16.7%) | 0 | 0 |
Abdominal pain | 1 (16.7%) | 1 (16.7%) | 0 | 0 |
Decreased appetite | 2 (33%) | 0 | 0 | 0 |
Cutaneous rash | 2 (33%) | 0 | 0 | 0 |
Hypertension | 1 (16.7%) | 0 | 0 | 0 |
Venous thromboembolism | 0 | 0 | 1 (16.7%) | 0 |
Colitis | 1 (16.7%) | 0 | 0 | 0 |
Creatinin increased | 0 | 1 (16.7%) | 0 | 0 |
Dyspnea | 0 | 1 (16.7%) | 0 | 0 |
Headache | 0 | 1 (16.7%) | 0 | 0 |
Hearing impairment | 0 | 1 (16.7%) | 0 | 0 |
Hyperthyroidism | 1 (16.7%) | 0 | 0 | 0 |
Mucositis | 1 (16.7%) | 0 | 0 | 0 |
Nervous system disorder | 0 | 1 (16.7%) | 0 | 0 |
Peripheral motor neuropathy | 1 (16.7%) | 0 | 0 | 0 |
Platelet count decreased | 1 (16.7%) | 0 | 0 | 0 |
Renal and urinary disorder | 0 | 1 (16.7%) | 0 | 0 |
Supraventricular tachycardia | 1 (16.7%) | 0 | 0 | 0 |
Weight loss | 1 (16.7%) | 0 | 0 | 0 |